Navigation Links
Respironics to Webcast Fiscal 2008 First Quarter Conference Call
Date:10/17/2007

MURRYSVILLE, Penn., Oct. 17 /PRNewswire-FirstCall/ -- Respironics, Inc. (Nasdaq: RESP), a recognized resource in the medical device market, announced today that it intends to release its first quarter results for the period ending September 30, 2007 on Thursday October 25, 2007. In conjunction with this release and to review the Company's results and business outlook, Respironics will host a conference call that will be broadcast simultaneously live over the Internet.

Individuals wishing to participate on the Webcast, to be held at 8:30 a.m. EST on Thursday October 25, 2007, can access the event at the Company's web site at http://www.respironics.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. The online archive of the broadcast will be available within 2 hours of the live call and will be available for 30 days.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in 141 countries and employs over 5,100 associates worldwide. Further information can be found on the Company's Web site: http://www.respironics.com.

FORWARD-LOOKING STATEMENT

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the results of clinical trials; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major natural disaster, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

(C) 2007 Respironics, Inc. and its affiliates. All rights reserved.


'/>"/>
SOURCE Respironics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. BoneCare doubles options and profits as fiscal year closes
3. Sonic Foundry Reports Fiscal 2003 Results
4. The Genesis of Gendicine: The Story Behind the First Gene Therapy
5. Midwest life science stocks sizzle in a tepid first quarter
6. Morgridge Institute for Research seeks first CEO
7. Sonic Foundry reports first cash-positive quarter
8. Angel investors commit $12.7B in first half of `06
9. Aurora team implants Wisconsins first total artificial heart
10. First half of 2006 roundup: Big Pharma trumps biotech
11. GE announces first installation of Discovery VCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem Cells ... with Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global Medical ... the latest adipose and bone marrow therapies. , Through the new collaboration, ...
(Date:2/9/2016)... FALLS, N.J. , Feb. 9, 2016 /PRNewswire/ ... a biotechnology company specializing in the development and ... health of damaged tissues and organs, recently reported ... for the first quarter of 2016. ... began the new 2015 fiscal year in the ...
(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric ... he will focus on acquiring new accounts and work closely with existing Tunnell clients ... “Fred brings to our European clients more than 15 years of experience in the ...
(Date:2/9/2016)... 2016  DNAtrix, a clinical stage, biotechnology ... that its lead product, DNX-2401, has been ... orphan medicinal product for the treatment of ... strikes approximately 25,000 people a year in ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):